Nadia Farhanah Syafhan
Division Of Clinical Pharmacy, Faculty Of Pharmacy, Universitas Indonesia, Depok 16424, West Java, Indonesia | Universitas Indonesia Hospital, Jl. Prof. DR. Bahder Djohan, Pondok Cina, Beji, Depok, West Java 16424, Indonesia

Published : 25 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search
Journal : Jurnal Farmasi Indonesia

Faktor-Faktor yang Memengaruhi Efektivitas Hematinik pada Pasien Hamil di Puskesmas Kecamatan Matraman Nadia Farhanah Syafhan; Meiliani Shara Suria L; Azizahwati
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 12 No. 1 (2020): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (327.669 KB) | DOI: 10.35617/jfionline.v12i1.61

Abstract

The government has been giving hematinic that contains 200 mg of ferro sulfas and 0.25 mg of folic acid to pregnant patient since 1970, but anaemia prevalence in pregnant patient at Matraman primary health care has been still relatively high. This research aimed to analyze factors that were influencing hematinic effectiveness that has been used by pregnant patient at Matraman primary health care. The method used for this research was cross-sectional study with purposive sampling technique. Data was obtained from the result of laboratory test for haemoglobin level and interview using valid and reliable questionnaire. Respondents of this research were pregnant patient who used hematinics that were given from government and their haemoglobin level had been measured at least twice during their pregnancy. Total respondent who met the inclusion criteria were 85 patients. Based on the result, there were significant association between tea consumption habits and haemoglobin level (p=0.000) and also significant association between patient adherence on hematinic consumption and haemoglobin level (p=0.004). But there were no significant association between dietary habit and haemoglobin level (p=0,105) and between how to consume hematinic and haemoglobin level (p=0,684). This study showed factors influencing hematinic effectiveness were tea consumption habits and patient adherence on hematinic consumption.
Reaksi Merugikan Obat Kanker Berbasis Antrasiklin pada Pasien Kanker Payudara di RS Kanker Dharmais Chairunnisa, Dian Fitri; Harahap, Yahdiana; Syafhan, Nadia Farhanah; Purwanto, Denni Joko
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 16 No. 1 (2024): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35617/jfionline.v16i1.164

Abstract

Breast cancer is the type of cancer that most often affects women worldwide. Doxorubicin is an anthracycline class, a first-line anticancer therapy with clinical activity in breast cancer. Doxorubicin can cause cardiotoxic effects due to the formation of doxorubicinol as its primary metabolite. Adverse drug reactions also vary depending on the chemotherapy regimen. This study aimed to determine the adverse reactions to anthracycline-based drugs that breast cancer patients often experience. This observational descriptive study was conducted from April to July 2022 at the Dharmais Cancer Hospital, Jakarta. The sample in this study was breast cancer patients undergoing chemotherapy with anthracycline-based regimens. Data were collected through interviews and observation of medical records, which were analyzed by univariate analysis. The results showed that the most frequent drug reaction was alopecia, with a percentage of 97.1%. They were followed by nausea at 85.7%, vomiting at 71.4% and pain at 65.7%. The fastest time for nausea to appear is within 18-24 hours (peak days 2 to 3) after chemotherapy. Did not experience a decrease in left ventricular ejection fraction by 34.3%, and 65.7% experienced a reduction in left ventricular ejection fraction after doxorubicin chemotherapy. Patients who underwent a reduction in left ventricular ejection fraction after doxorubicin chemotherapy had a decrease in ejection fraction <10%, and no patients experienced a decline in left ventricular ejection fraction >10%. Breast cancer patients who receive anthracycline-based treatment can experience adverse drug reactions, including nausea, vomiting, alopecia, pain and decreased left ventricular ejection fraction.
Pengaruh Faktor Risiko terhadap Kejadian Peningkatan Kadar Enzim Transaminase pada Pasien Covid-19 dengan Terapi Tocilizumab Nasution, Izza Aulia Rizqika; Andrajati, Retnosari; Syafhan, Nadia Farhanah; Imaniar, Rania
JFIOnline | Print ISSN 1412-1107 | e-ISSN 2355-696X Vol. 15 No. 1 (2023): Jurnal Farmasi Indonesia
Publisher : Pengurus Pusat Ikatan Apoteker Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (398.476 KB) | DOI: 10.35617/jfionline.v15i1.137

Abstract

Abstract: Tocilizumab is an anti-IL-6 which is recommended as cytokine release syndrome therapy in the treatment of Covid-19. One of the side effects of tocilizumab that can occur is hepatotoxicity, from mild elevated transaminases to severe drug-induced liver injury (DILI). Currently, research related to tocilizumab hepatotoxicity and the risk factors affecting Covid-19 patients is limited and still needs to conduct. This research is an observational study with cross-sectional design. Data collection was carried out retrospectively using secondary data obtained from medical records department, patients with Covid-19 at Universitas Indonesia Hospital in 2020-2021. Patients confirmed with positive Covid-19 receiving Tocilizumab therapy in medical record were included in this study. Patient demographics, clinical diagnoses, laboratory examinations, history of others medication were also reviewed. Patients with less than 18 years old, incomplete medical record data, and referred to other hospitals were excluded. The sampling technique used was total sampling, namely all patients who met the inclusion criteria were taken as subject in this research. Chi-square test was used to analyze the relationship between each risk factors and the incidence of elevated transaminases. The results of Chi-square test showed that several risk factors significantly increased the incidence of elevated transaminases in patients given tocilizumab therapy, including age, obesity, diabetes mellitus, and ceftriaxone as antibiotic therapy.